Sunrest Lifescie

Why is Sunrest Lifescience Ltd falling/rising?

As of 18-Jul, Sunrest Lifescience Ltd's stock price is at 35.00, unchanged from the previous session. Despite some short-term gains, the stock has significantly declined over the year and is experiencing reduced investor participation.

As of 18-Jul, Sunrest Lifescience Ltd's stock price is currently at 35.00, showing no change from the previous trading session. The stock has experienced a decline of 1.69% over the past week, while the benchmark Sensex has increased by 0.53%. Over the last month, the stock has risen by 3.24%, outperforming the Sensex, which gained 1.03%. However, year-to-date, Sunrest Lifescience Ltd has seen a significant drop of 15.76%, compared to a smaller decline of 6.87% in the Sensex. The stock has also fallen by 33.96% over the past year, while the Sensex has only decreased by 3.09%.<BR><BR>Today's performance indicates that the stock has outperformed its sector by 0.74%. Despite this, it is important to note that the stock's moving averages show mixed signals; it is higher than the 20-day moving average but lower than the 5-day, 50-day, 100-day, and 200-day moving averages. Additionally, there has been a notable decline in investor participation, with delivery volume dropping by 54.55% against the 5-day average. This suggests a decrease in trading activity, which could contribute to the stock's overall performance.<BR><BR>In summary, while Sunrest Lifescience Ltd has shown some positive movement in the short term, the overall trend indicates a significant decline over longer periods, coupled with reduced investor participation, which may be contributing to the stock's current price stability at 35.00.

Which are the latest news on Sunrest Lifescie?

What does Sunrest Lifescie do?

Sunrest Lifescience Ltd markets OTC generic pharmaceutical products and operates in the micro-cap market, with a recent net sales of 6 Cr and net profit of 1 Cr as of June 2023. The company, converted to a Public Limited Company in March 2023, has a market cap of INR 29 Cr.

Overview: <BR>Sunrest Lifescience Ltd is engaged in the marketing of OTC generic pharmaceutical products within the healthcare services industry and falls under the micro-cap market category.<BR><BR>History: <BR>Sunrest Lifescience Ltd was originally incorporated as "Sunrest Lifescience Private Limited" in 2017. It was converted into a Public Limited Company and renamed on March 21, 2023. The most recent quarterly results reported net sales and net profit for June 2023.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 6 Cr (Quarterly Results - Jun 2023) <BR>Most recent Net Profit: 1 Cr (Quarterly Results - Jun 2023) <BR>Market-cap value: INR 29 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 7.00 <BR>Industry P/E: 21 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.72 <BR>Return on Equity: 20.17% <BR>Price to Book: 1.43 <BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

How big is Sunrest Lifescie?

As of 10th June, Sunrest Lifescience Ltd has a market capitalization of 29.00 Cr, with recent net sales of 5.64 Cr and a net profit of 0.75 Cr for the quarter ending June 2023.

As of 10th June, Sunrest Lifescience Ltd has a market capitalization of 29.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest quarter ending June 2023, Sunrest Lifescience reported Net Sales of 5.64 Cr and a Net Profit of 0.75 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, where Shareholder's Funds are valued at 16.19 Cr and Total Assets amount to 35.13 Cr.

Who are in the management team of Sunrest Lifescie?

The management team of Sunrest Lifescie includes Juhi Sawajani (Chairperson), Nikhilkumar Y Thakkar (Managing Director), Amitbhai Shambhulal Thakkar (Whole-time Director), Bharatkumar V Thakkar (Executive Director), Bhagyesh Kiritbhai Parekh (Non-Executive Director), Avani Shah (Independent Director), and Nishi B Shah (Company Secretary & Compliance Officer).

The management team of Sunrest Lifescie includes the following members:<BR><BR>1. **Juhi Sawajani** - Chairperson<BR>2. **Nikhilkumar Y Thakkar** - Managing Director<BR>3. **Amitbhai Shambhulal Thakkar** - Whole-time Director<BR>4. **Bharatkumar V Thakkar** - Executive Director<BR>5. **Bhagyesh Kiritbhai Parekh** - Non-Executive Director<BR>6. **Avani Shah** - Independent Director<BR>7. **Nishi B Shah** - Company Secretary & Compliance Officer<BR><BR>If you need more specific information about any of these individuals or their roles, feel free to ask!

Who are the peers of the Sunrest Lifescie?

Sunrest Lifescie's peers include Galaxy Medicare, Centenial Surgic, and Deccan Healthcar, among others. Sunrest Lifescie has good management risk and growth but a lower 1-year return of -35.70% compared to its peers.

Peers: The peers of Sunrest Lifescie are Galaxy Medicare, Centenial Surgic, Chennai Meena, Deccan Healthcar, Tejnaksh Health., GKB Ophthalmics, Samsrita Labs, Transgene Biotek, N G Industries, and Adeshwar Meditex.<BR><BR>Quality Snapshot: Excellent management risk is observed at Galaxy Medicare and N G Industries, while Good management risk is found at Sunrest Lifescie. Below Average management risk is noted at Centenial Surgic, Deccan Healthcar, Tejnaksh Health., GKB Ophthalmics, and Adeshwar Meditex, and the rest. Growth is Excellent at Sunrest Lifescie, Good at Deccan Healthcar and GKB Ophthalmics, and Below Average at Galaxy Medicare, Centenial Surgic, Tejnaksh Health., and N G Industries, and the rest. Average capital structure is seen at Sunrest Lifescie and Centenial Surgic, while Good capital structure is found at Galaxy Medicare, Deccan Healthcar, GKB Ophthalmics, and N G Industries, and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Centenial Surgic at 0.00%, while the peer with the lowest is Sunrest Lifescie at -35.70%, indicating that Sunrest Lifescie has a significantly lower return compared to its peers. Additionally, several peers, including Galaxy Medicare, Sunrest Lifescie, and others, have negative six-month returns.

Is Sunrest Lifescie overvalued or undervalued?

As of November 27, 2025, Sunrest Lifescie has shifted from a fair to an attractive valuation grade, indicating it is undervalued with a PE ratio of 9.37 and strong growth potential compared to peers, despite a year-to-date return of -15.24% against the Sensex's 10.87%.

As of 27 November 2025, the valuation grade for Sunrest Lifescie has moved from fair to attractive, indicating a positive shift in its valuation outlook. The company appears to be undervalued, supported by a PE ratio of 9.37, an EV to EBITDA of 8.21, and a PEG ratio of 0.01, which suggests significant growth potential relative to its price. <BR><BR>In comparison to its peers, Sunrest Lifescie stands out with a more favorable PE ratio than Elitecon International, which is very expensive at 207.04, and MMTC, which is risky at 129.91. Additionally, PTC India, classified as very attractive, has a lower PE of 7.33, further highlighting Sunrest's competitive positioning in the market. Despite recent underperformance against the Sensex, with a year-to-date return of -15.24% compared to the Sensex's 10.87%, the company's strong fundamentals suggest it may present a compelling investment opportunity.

How has been the historical performance of Sunrest Lifescie?

Sunrest Lifescie reported a consolidated net profit of 2.01 crore for the year ending March 2025, with net sales and total operating income both at 33.41 crore. The company showed growth in profitability, a strengthened balance sheet, and positive cash flow from operating activities of 1.00 crore.

Answer:<BR>The historical performance of Sunrest Lifescie shows a consolidated net profit of 2.01 crore for the year ending March 2025, with net sales amounting to 33.41 crore. The total operating income for the same period was also 33.41 crore, while total expenditure, excluding depreciation, was 30.39 crore, resulting in an operating profit (PBDIT) of 3.02 crore. The profit before tax stood at 2.62 crore, leading to a profit after tax of 2.01 crore after accounting for tax expenses of 0.61 crore. The earnings per share (EPS) were reported at 4.69, with a PAT margin of 6.02%. <BR><BR>In terms of balance sheet metrics, the total assets of Sunrest Lifescie reached 35.13 crore, with total liabilities also at 35.13 crore, indicating a balanced position. The company’s shareholder's funds increased to 16.19 crore, up from 14.19 crore in the previous year. Long-term borrowings rose to 4.08 crore, while total debt remained stable at 6.16 crore. The book value per share adjusted to 37.72, reflecting a significant increase from previous years. Cash flow from operating activities showed a positive trend with 1.00 crore for the year, contrasting with a negative cash flow in the prior year. Overall, Sunrest Lifescie's financial performance indicates growth in sales and profitability, alongside a strengthening balance sheet.<BR><BR>Breakdown:<BR>Sunrest Lifescie's financial performance for the year ending March 2025 reveals a consolidated net profit of 2.01 crore, supported by net sales and total operating income both at 33.41 crore. The company incurred total expenditure of 30.39 crore, leading to an operating profit of 3.02 crore. After accounting for interest and tax, the profit before tax was 2.62 crore, resulting in a profit after tax of 2.01 crore. The earnings per share were reported at 4.69, with a PAT margin of 6.02%. On the balance sheet, total assets and total liabilities both stood at 35.13 crore, while shareholder's funds increased to 16.19 crore. Long-term borrowings rose to 4.08 crore, and total debt remained at 6.16 crore. The book value per share adjusted to 37.72, indicating growth. Cash flow from operating activities was positive at 1.00 crore, contrasting with the previous year's negative cash flow, highlighting a recovery in operational efficiency.

Who are the top shareholders of the Sunrest Lifescie?

The top shareholder of Sunrest Lifescie is Nikhilkumar Yashvntlal Thakkar, with a 17.48% stake, while the highest public shareholder is Shardaben Dalsukhram Thakkar at 1.49%. Individual investors collectively own 24.94% of the shares, and there are no pledged promoter holdings or mutual funds/foreign institutional investors involved.

The top shareholders of Sunrest Lifescie include the promoters, with Nikhilkumar Yashvntlal Thakkar holding the highest stake at 17.48%. There are no pledged promoter holdings, and the company does not have any mutual funds or foreign institutional investors (FIIs) holding shares. The highest public shareholder is Shardaben Dalsukhram Thakkar, who holds 1.49%. Additionally, individual investors collectively hold 24.94% of the company's shares.

What is the technical trend for Sunrest Lifescie?

As of May 16, 2025, Sunrest Lifescie has shifted to a bearish trend, supported by a bearish MACD, moving averages, and Bollinger Bands, indicating moderate strength in the bearish stance.

As of 16 May 2025, the technical trend for Sunrest Lifescie has changed from mildly bearish to bearish. The weekly MACD is bearish, and the daily moving averages confirm a bearish stance. The Bollinger Bands on the weekly chart also indicate a bearish trend, while the KST is bearish as well. The OBV shows a mildly bearish trend on both the weekly and monthly time frames. Overall, the current technical stance is bearish with moderate strength, driven primarily by the bearish MACD and moving averages.

When is the next results date for Sunrest Lifescie?

No Upcoming Board Meetings

Has Sunrest Lifescie declared dividend?

No Dividend History Available